Neuroimmunomodulatory steroids in alzheimer dementia

Journal of Steroid Biochemistry and Molecular Biology

Volumn 119, Issue 3-5, 2010, Pages 97-104

  Hampl, Richard ^a   Bičíková, Marie ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

Alzheimer disease; Apoptosis; Autoimmunity; Glycoregulation; Steroids

Indexed keywords

AMYLOID BETA PROTEIN; GLUCOCORTICOID; PRASTERONE; REACTIVE OXYGEN METABOLITE; STEROID; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CALCIUM TRANSPORT; CHOLINERGIC SYSTEM; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE COURSE; GLUCOSE METABOLISM; HUMAN; METABOLITE; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NEUROMODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; AUTOIMMUNITY; BRAIN; DEHYDROEPIANDROSTERONE; GLUCOCORTICOIDS; GLYCOSYLATION; HUMANS; NEUROIMMUNOMODULATION; STEROIDS; TAU PROTEINS;

EID: 77950296602     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.02.007     Document Type: Review

References (110)

1. Morfin R., Stárka L. Neurosteroid 7-hydroxylation products in the brain. Int. Rev. Neurobiol. 2001, 46:79-95.
2. Morfin R., Lafaye P., Cotillon A.C., Nato F., Chmielewski V., Pompon D. 7-Alpha-hydroxy-dehydroepiandrosterone and immune response. Ann. N. Y. Acad. Sci. 2000, 917:971-982.
3. Muller C., Hennebert O., Morfin R. The native anti-glucocorticoid paradigm. J. Steroid Biochem. Mol. Biol. 2006, 100:95-105.
4. Brooks W.M., Lynch P.J., Ingle C.C., Hatton A., Emson P.C., Faull R.L.M., Starkey M.P. Gene expression profiles of metabolic enzyme transcripts in Alzheimer disease. Brain Res. 2007, 1127:127-135.
5. Fowler J.S., Ido T. Initial and subsequent approach for the synthesis of 18FDG. Semin. Nucl. Med. 2002, 32:6-12.
6. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imageing 2005, 32:486-510.
7. Schönknecht P., Henze M., Hunt A., Klinga K., Haberkorn U., Schröder J. Hippocampal glucose metabolism is associated with cerebrospinal fluid estrogen levels in postmenopausal women with Alzheimer disease. Psychiatry Res. 2003, 124:125-127.
8. Brinton R.D. estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer disease. Adv. Drug. Deliv. Rev. 2008, 60:1504-1511.
9. Csernansky J.G., Dong H., Fagan A.M., Wang L., Xiong G., Holtzman D.M., Morris J.C. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am. J. Psychiatry 2006, 163:2164-2169.
10. Magri F., Cravello L., Barili L., Sarra S., Cinchetti W., Salmoiraghi F., Micale G., Ferrari E. Stress and dementia: the role of the hypothalamic-pituitary-adrenal axis. Ageing Clin. Exp. Res. 2006, 18:167-170.
11. De Leon M.J., McRae T., Rusinek H., Convit A., De Santi S., Tarshish C., Golomb J., Volkow N., Daisley K., Orentreich N., McEwen B. Cortisol reduces hippocampal glucose metabolism in the normal elderly, but not in Alzheimer disease. J. Clin. Endocrinol. Metab. 1997, 82:3251-3259.
12. Bigl M., Brückner M.K., Arendt T., Bigl V., Eschrich K. Activities of key glycolytic enzymes in the brains of patients with Alzheimer disease. J. Neural Transm. 1999, 106:499-511.
13. Bigl M., Bleyl A.D., Zedlick D., Arendt T., Bigl V., Eschrich K. Changes of activity and isozyme pattern of phosphofructokinase in the brains of patients with Alzheimer disease. J. Neurochem. 1996, 67:1164-1171.
14. Gibson G.E., Sheu K.F., Blass J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm. 1998, 105:855-870.
15. Landfield P.W., Blalock E.M., Chen K.C., Porter N.M. A new glucocorticoid hypothesis of brain ageing: implication for Alzheimer's disease. Curr. Alzheimer Res. 2007, 4:205-212.
16. Cochrane Database Syst. Rev. 18 (2007) CD000304.
17. Schwartz A.G., Pashko L.L. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res. Rev. 2004, 3:171-187.
18. Mamelak M. Alzheimer' s disease, oxidative stress and gammahydroxybutyrate. Neurobiol. Aging 2007, 28:1340-1360.
19. Chalbot S., Morfin R. Dehydroepiandrosterone metabolites and their interactions in humans. Drug Metabol. Drug Interact. 2006, 22:1-23.
20. Yau J.L., Rasmuson S., Andrew R., Graham M., Noble J., Olsson T., Fuchs E., Lathe R., Seckl J.R. Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer disease. Neuroscience 2003, 121:307-314.
21. Muller C., Pompon D., Urban P., Morfin R. Inter-conversion of 7alpha- and 7beta-hydroxy-dehydroepiandrosterone by the human 11beta-hydroxysteroid dehydrogenase type I. J. Steroid Biochem. Mol. Biol. 2006, 99:215-222.
22. Hennebert O., Pernelle C., Ferroud C., Morfin R. 7Alpha- and 7beta-hydroxy-epiandrosterone as substrates and inhibitors for the human 11beta-hydroxysteroid dehydrogenase type I. J. Steroid Biochem. Mol. Biol. 2007, 105:159-165.
23. Münch G., Schinzel R., Loske C., Wong A., Durany N., Li J.J., Vlassara H., Smith M.A., Perry G., Riederer P. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation end products. J. Neural Transm. 1998, 105:439-461.
24. Rönnemaa E., Zethelius B., Sundelöf J., Sundström J., Degerman-Gunnarsson M., Berne C., Lannfelt L., Kilander L. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008, 71:1065-1071.
25. Sun M.K., Alkon D.L. Links between Alzheimer disease and diabetes. Drugs Today (Barc.) 2006, 42:481-489.
26. Neumann K.F., Rojo L., Navarrete L.P., Farías G., Reyes P., Maccioni R.B. Insulin resistance and Alzheimer disease: molecular links & clinical implications. Curr. Alzheimer Res. 2008, 5:438-447.
27. Craft S. Insulin resistance and Alzheimer disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 2007, 4:147-152.
28. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol. 2009, 66:300-305.
29. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signalling mechanisms in Alzheimer disease-is this type III diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
30. Alonso A., González C. Relationship between non-genomic actions of estrogens and insulin resistace. Infect. Disord. Drug Targets 2008, 8:48-51.
31. Ordóñez P., Moreno M., Alonso A., Llaneza P., Díaz F., González C. 17beta-Estradiol and/or progesterone protect from insulin resistance in STZ-induced diabetic rats. J. Steroid Biochem. Mol. Biol. 2008, 111:287-294.
32. Farrell J.B., Deshmukh A., Baghaie A.A. Low testosterone and the association with type II diabetes. Diabetes Educ. 2008, 34:799-806.
33. Traish A.M., Saad F., Guay A. The dark side of testosterone deficiency: II. Type II diabetes and insulin resistance. J. Androl. 2009, 30:23-32.
34. Gillett M.J., Martins R.N., Clarnette R.M., Chubb S.A., Bruce D.G., Yeap B.B. Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia, J. Alzheimers Dis. 2003, 5:267-269.
35. Okun M.S., DeLong M.R., Hanfelt J., Gearing M., Levey A. Plasma testosterone levels in Alzheimer and Parkinson diseases. Neurology 2004, 62:411-413.
36. Garcia-Segura L.M., Dueñas M., Busiguina S., Naftolin F., Chowen J.A. Gonadal hormone regulation of neuronal-glial interactions in the developing neuroendocrine hypothalamus. J. Steroid Biochem. Mol. Biol. 1995, 53:293-298.
37. Cherrier M.M. Testosterone effects on cognition in health and disease. Front. Horm. Res. 2009, 37:150-162.
38. Wilkins C.H., Sheline Y.I., Roe C.M., Birge S.J., Morris J.C. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am. J. Geriatr. Psychiatry 2006, 14:1032-1040.
39. Evatt M.L., Delong M.R., Khazai N., Rosen A., Triche S., Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch. Neurol. 2008, 65:1348-1352.
40. Mruthinti S., Schade R.F., Harrell D.U., Gulati N.K., Swamy-Mruthinti S., Lee G.P., Buccafusco J.J. Autoimmunity in Alzheimer disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: complication of diabetes. Curr. Alzheimer Res. 2006, 3:229-235.
41. Sato T., Shimogaito N., Wu X., Kikuchi S., Yamagishi S., Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer disease. Am. J. Alzheimers Dis. Other Demen. 2006, 21:197-208.
42. Brignardello E., Runzo C., Aragno M., Catalano M.G., Cassader M., Perin P.C., Boccuzzi G. Dehydroepiandrosterone administration counteracts oxidative imbalance and advanced glycation end product formation in type II diabetic patients. Diabetes Care 2007, 30:2922-2927.
43. Chen L., Liu Y., Cui B., Mi Q., Huang Y., Fan L., Chen Q., Tang J., Ferro A., Ji Y. 17Beta-oestradiol partially attenuates the inhibition of nitric oxide synthase-3 by advanced glycation end-products in human platelets. Clin. Exp. Pharmacol. Physiol. 2007, 34:972-978.
44. Gasic-Milenkovic J., Loske C., Münch G. Advanced glycation end products cause lipid peroxidation in the human neuronal cell line SH-SY5Y. J. Alzheimers Dis. 2003, 5:25-30.
45. Tabaton M., Tamagno E. The molecular link between beta- and gamma-secretase activity on the amyloid beta precursor protein. Cell. Mol. Life Sci. 2007, 64:2211-2218.
46. Vassar R. Beta-secretase (BACE) as a drug target for Alzheimer disease. Adv. Drug Deliv. Rev. 2002, 54:1589-1602.
47. Cole S.L., Vassar R. BACE1 structure and function in health and Alzheimer disease. Curr. Alzheimer Res. 2008, 5:100-120.
48. Goodenough S., Schäfer M., Behl C. Estrogen-induced cell signalling in a cellular model of Alzheimer disease. J. Steroid Biochem. Mol Biol. 2003, 84:301-305.
49. Xiong H., Callaghan D., Jones A., Walker D.G., Lue L.F., Beach T.G., Sue L.I., Woulfe J., Xu H., Stanimirovic D.B., Zhang W. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol. Dis. 2008, 29:422-437.
50. Green K.N., Billings L.M., Roozendaal B., McGaugh J.L., LaFerla F.M. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer disease. J. Neurosci. 2006, 26:9047-9056.
51. Tamagno E., Guglielmotto M., Bardini P., Santoro G., Davit A., Di Simone D., Danni O., Tabaton M. Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiol. Dis. 2003, 14:291-301.
52. Rosario E.R., Pike C.J. Androgen regulation of beta-amyloid protein and the risk of Alzheimer disease. Brain Res. Rev. 2008, 57:444-453.
53. Pike C.J., Nguyen T.V., Ramsden M., Yao M., Murphy M.P., Rosario E.R. Androgen cell signalling pathways involved in neuroprotective actions. Horm. Behav. 2008, 53:693-705.
54. Sousa J.C., Cardoso I., Marques F., Saraiva M.J., Palha J.A. Transthyretin and Alzheimer disease: where in the brain?. Neurobiol. Ageing 2007, 28:713-718.
55. Tang Y.P., Haslam S.Z., Conrad S.E., Sisk C.L. Estrogen increases brain expression of the mRNA encoding transthyretin, an amyloid beta scavenger protein. J. Alzheimers Dis. 2004, 6:413-420.
56. Green N.S., Foss T.R., Kelly J.W. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14545-14550.
57. Stoothoff W.H., Johnson G.V. Tau phosphorylation: physiological and pathological consequences. Biochim. Biophys. Acta 2005, 1739:280-297.
58. Mi K., Johnson G.V. The role of tau phosphorylation in the pathogenesis of Alzheimer disease. Curr. Alzheimer Res. 2006, 3:449-463.
59. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer disease. J. Alzheimers Dis. 2006, 9(Suppl. 3):309-317.
60. Perkinton M.S., Ip J.K., Wood G.L., Crossthwaite A.J., Williams R.J. Phosphatidylinositol 3-kinase is a central mediator of NMDA receptor signalling to MAP kinase (Erk1/2), Akt/PKB and CREB in striatal neurones. J. Neurochem. 2002, 80:239-254.
61. Zhao W.G., Ravindranath L., Mohamed A.S., Zohar O., Chen G.H., Lyketsos C.G., Etcheberrigaray R., Alkon D.L. MAP kinase signalling cascade dysfunction specific to Alzheimer disease in fibroblasts. Neurobiol. Dis. 2002, 11:166-183.
62. Sadik G., Tanaka T., Kato K., Yamamori H., Nessa B.N., Morihara T., Takeda M. Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: implications for the mechanism of tau aggregation. J. Neurochem. 2009, 108:33-43.
63. Ferrer I., Barrachina M., Tolnay M., Rey M.J., Vidal N., Carmona M., Blanco R., Puig B. Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease. Brain Pathol. 2003, 13:62-78.
64. Ferrer I., Gomez-Isla T., Puig B., Freixes M., Ribé E., Dalfó E., Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer disease and tauopathies. Curr. Alzheimer Res. 2005, 2:3-18.
65. Wang J.Z., Grundke-Iqbal I., Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 2007, 25:59-68.
66. Alvarez-de-la-Rosa M., Silva I., Nilsen J., Pérez M.M., García-Segura L.M., Avila J., Naftolin F. Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer disease. Ann. N. Y. Acad. Sci. 2005, 1052:210-224.
67. Shi H.R., Zhu L.Q., Wang S.H., Liu X.A., Tian Q., Zhang Q., Wang Q., Wang J.Z. 17Beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner. J. Neural Transm. 2008, 115:879-888.
68. Liu X.A., Zhu L.Q., Zhang Q., Shi H.R., Wang S.H., Wang Q., Wang J.Z. Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A. Neurochem. Res. 2008, 33:1811-1820.
69. Sotiropoulos I., Catania C., Riedemann T., Fry J.P., Breen K.C., Michaelidis T.M., Almeida O.F. Glucocorticoids trigger Alzheimer disease-like pathobiochemistry in rat neuronal cells expressing human tau. J. Neurochem. 2008, 107:385-397.
70. Arshavsky Y.L. Alzheimer's disease, brain immune privilege and memory: a hypothesis. J. Neural Transm. 2006, 113:1697-1707.
71. McEwen B.S., Coirini H., Westlind-Danielsson A., Frankfurt M., Gould E., Schumacher M., Woolley C. Steroid hormones as mediators of neural plasticity. J. Steroid Biochem. Mol Biol. 1991, 39:223-232.
72. Lathe R. Steroid and sterol 7-hydroxylation: ancient pathways. Steroids 2002, 67:967-977.
73. Morfin R. Involvement of steroids and cytochromes P(450) species in the triggering of immune defenses. J. Steroid Biochem. Mol. Biol. 2002, 80:273-290.
74. Solerte S.B., Fioravanti M., Schifino N., Cuzzoni G., Fontana I., Vignati G., Govoni S., Ferrari E. Dehydroepiandrosterone sulfate decreases the interleukin-2-mediated overactivity of the natural killer cell compartment in senile dementia of the Alzheimer type. Dement. Geriatr. Cogn. Disord. 1999, 10:21-27.
75. Sala G., Galimberti G., Canevari C., Raggi M.E., Isella V., Facheris M., Appollonio I., Ferrarese C. Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol. Ageing 2003, 34:909-914.
76. Yu S., Holsboer F., Almeida O.F. Neuronal actions of glucocorticoids: focus on depression. J. Steroid Biochem. Mol. Biol. 2008, 108:300-309.
77. M. Ogundare, S. Theofilopoulos, A. Lockhart, L.J. Hall, E. Arenas, J. Sjovall, A.G. Brenton, Y. Wang, W.J. Griffiths, Cerebrospinal fluid steroidomics: Are bioactive bile acids present in the brain? J. Biol. Chem. (December) (2009) (ahead of print).
78. Gilardi F., Mitro N., Godio C., Scotti E., Caruso D., Crestani M., De Fabiani E. The pharmacological exploitation of cholesterol 7alpha-hydroxylase, the key enzyme in bile acid synthesis: from binding resins to chromatin remodelling to reduce plasma cholesterol. Pharmacol. Ther. 2007, 116:449-472.
79. Davis R.A., Miyake J.H., Hu T.Y., Spann N.J. Regulation of cholesterol-7alpha-hydroxylase: BAREly missing a SHP. J. Lipid Res. 2002, 43:533-543.
80. Li T., Jahan A., Chiang J.Y. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology 2006, 43:1202-1210.
81. Dulos J., Kaptein A., Kavelaars A., Heijnen C., Boots A. Tumour necrosis factor-alpha stimulates dehydroepiandrosterone metabolism in human fibroblast-like synoviocytes: a role for nuclear factor-kappaB and activator protein-1 in the regulation of expression of cytochrome p450 enzyme 7b. Arthritis Res. Ther. 2005, 7:R1271-R1280.
82. Dhikav V., Anand K.S. Glucocorticoids may initiate Alzheimer disease: a potential therapeutic role for mifepristone (RU-486). Med. Hypotheses 2007, 68:1088-1092.
83. Belanoff J.K., Jurik J., Schatzberg L.D., DeBattista C., Schatzberg A.F. Slowing the progression of cognitive decline in Alzheimer disease using mifepristone. J. Mol. Neurosci. 2002, 19:201-206.
84. DeBattista C., Belanoff J.K. C-1073 (mifepristone) in the adjunctive treatment of Alzheimer disease. Curr. Alzheimer Res. 2005, 2:125-129.
85. Pomara N., Hernando R.T., de la Pena C.B., Sidtis J.J., Cooper T.B., Ferris S. The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer disease. Neurochem. Res. 2006, 31:585-588.
86. Martignoni E., Costa A., Sinforiani E., Liuzzi A., Chiodini P., Mauri M., Bono G., Nappi G. The brain as a target for adrenocortical steroids: cognitive implications. Psychoneuroendocrinology 1992, 17:343-354.
87. Herman J.P., Seroogy K. Hypothalamic-pituitary-adrenal axis, glucocorticoids, and neurologic disease. Neurol. Clin. 2006, 24:461-481.
88. Nichols N.R., Agolley D., Zieba M., Bye N. Glucocorticoid regulation of glial responses during hippocampal neurodegeneration and regeneration. Brain Res. Brain Res. Rev. 2005, 48:287-301.
89. Charalampopoulos I., Alexaki V.I., Tsatsanis C., Minas V., Dermitzaki E., Lasaridis I., Vardouli L., Stournaras C., Margioris A.N., Castanas E., Gravanis A. Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in ageing. Ann. N. Y. Acad. Sci. 2006, 1088:139-152.
90. Alexaki V.I., Charalampopoulos I., Kampa M., Nifli A.P., Hatzoglou A., Gravanis A., Castanas E. Activation of membrane estrogen receptors induce pro-survival kinases. J. Steroid Biochem. Mol. Biol. 2006, 98:97-110.
91. Charalampopoulos I., Margioris A.N., Gravanis A. Neurosteroid dehydroepiandrosterone exerts anti-apoptotic effects by membrane-mediated, integrated genomic and non-genomic pro-survival signalling pathways. J. Neurochem. 2008, 107:1457-1469.
92. Zhang L., Li B., Ma W., Barker J.L., Chang Y.H., Zhao W., Rubinow D.R. Dehydroepiandrosterone (DHEA) and its sulfated derivative (DHEAS) regulate apoptosis during neurogenesis by triggering the Akt signalling pathway in opposing ways. Brain Res. Mol. Brain Res. 2002, 98:58-66.
93. Lin S.Y., Cui H., Yusta B., Belsham D.D. IGF-I signalling prevents dehydroepiandrosterone (DHEA)-induced apoptosis in hypothalamic neurons. Mol. Cell. Endocrinol. 2004, 214:127-135.
94. Pike C.J. Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer disease. J. Neurochem. 1999, 72:1552-1563.
95. Peskind E.R., Raskind M.A., Wingerson D., Pascualy M., Thal L.J., Dobie D.J., Wilkinson C.W. Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: effects of Alzheimer disease and gender. Biol. Psychiatry 1996, 40:61-68.
96. Zhu X., Su B., Wang X., Smith M.A., Perry G. Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci. 2007, 64:2202-2210.
97. Onyango I., Khan S., Miller B., Swerdlow R., Trimmer P., Bennett P. Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer disease. J. Alzheimer's Dis. 2006, 9:183-193.
98. Shea T.B., Ortiz D. 17 Beta-estradiol alleviates synergistic oxidative stress resulting from folate deprivation and amyloid-beta treatment. J. Alzheimers Dis. 2003, 5:323-327.
99. Nilsen J. Estradiol and neurodegenerative oxidative stress. Front. Neuroendocrinol. 2008, 29:463-475.
100. Bastianetto S., Ramassamy C., Poirier J., Quirion R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res. Mol. Brain Res. 1999, 66:35-41.
101. Behl C., Lezoualc'h F., Trapp T., Widmann M., Skutella T., Holsboer F. Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology 1997, 138:101-106.
102. Yamamoto S., Wajima T., Hara Y., Nishida M., Mori Y. Transient receptor potential channels in Alzheimer disease. Biochim. Biophys. Acta 2007, 1772:958-967.
103. Dong X.X., Wang Y., Qin Z.H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 2009, 30:379-387.
104. O'Neill K., Chen S., Brinton R.D. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with ageing and Alzheimer disease. Exp. Neurol. 2004, 185:63-80.
105. Foradori C.D., Werner S.B., Sandau U.S., Clapp T.R., Handa R.J. Activation of the androgen receptor alters the intracellular calcium response to glutamate in primary hippocampal neurons and modulates sarco/endoplasmic reticulum calcium ATPase 2 transcription. Neuroscience 2007, 149:155-164.
106. Rupprecht R., Hauser C.A., Trapp T., Holsboer F. Neurosteroids: molecular mechanisms of action and psychopharmacological significance. J. Steroid Biochem. Mol. Biol. 1996, 56:163-168.
107. Schumacher M., Weill-Engerer S., Liere P., Robert F., Franklin R.J., Garcia-Segura L.M., Lambert J.J., Mayo W., Melcangi R.C., Parducz A., Suter U., Carelli C., Baulieu E.E., Akwa Y. Steroid hormones and neurosteroids in normal and pathological ageing of the nervous system. Prog. Neurobiol. 2003, 71:3-29.
108. Compagnone N.A., Mellon S.H. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front. Neuroendocrinol. 2000, 21:1-56.
109. Maurice T. Improving Alzheimer disease-related cognitive deficits with sigma1 receptor agonists. Drug News Perspect. 2002, 15:617-625.
110. Kim S.B., Hill M., Kwak Y.T., Hampl R., Jo D.H., Morfin R. Neurosteroids: cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics. J. Clin. Endocrinol. Metab. 2003, 88:199-206.